Volume 20, Issue 3 (May 2018) 20, 221–229; 10.4103/aja.aja_40_17
Role of chemotherapy in prostate cancer
Rita Nader1, Joelle El Amm2, Jeanny B Aragon-Ching3
1 Department of Internal Medicine, Lebanese American University, Beirut 1102 2801, Lebanon 2 Department of Internal Medicine, Division of Hematology and Oncology, Lebanese American University, Beirut 1102 2801, Lebanon 3 Genitourinary Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA 22031, USA
Correspondence: Dr. JB Aragon‐Ching (jeanny.aragon‐ching@inova.org)
Date of Submission 18-May-2017 Date of Acceptance 20-Jul-2017 Date of Web Publication 20-Oct-2017
Abstract |
Chemotherapy in prostate cancer (PCa) has undergone dramatic landscape changes. While earlier studies utilized varying chemotherapy regimens which were found to be largely palliative in nature and hardly resulted in durable or meaningful responses, docetaxel resulted in the first chemotherapy agent that showed improvement in overall survival in metastatic castration-resistant prostate cancer (mCRPC). However, combination chemotherapy or any agents added to docetaxel have failed to yield incremental benefits. The improvement in overall survival as well as secondary endpoints of prostate-specific antigen (PSA) and time to recurrence when using docetaxel in the metastatic hormone-sensitive state has changed the standard of care for treatment of newly diagnosed de novo metastatic PCa. There are also promising results in locally advanced PCa and high-risk PCa in both the neoadjuvant and adjuvant settings. This review summarizes the historical as well as the more contemporary use of chemotherapeutic agents in PCa in varying states and phases of disease.
Keywords: docetaxel; metastatic castration-resistant prostate cancer; prostate cancer
Full Text |
PDF |
|
|
Browse: 2228 |
|